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Background: Prosthetic joint infection (PJI) is an important failure mechanism of total joint arthroplasty (TJA). Here
we examine whether the particular genetic variants can lead to increased susceptibility to PJI development.
Results: We conducted a genetic-association study to determine whether PJI could be associated with functional
cytokine gene polymorphisms (CGP) influencing on innate immunity response. A case–control design was utilized
and previously published criteria for PJI were included to distinguish between cases and control subjects with/
without TJA. Six single nucleotide polymorphisms (SNPs) located in the genes for interleukin-1beta (SNP: IL1B-511,
+3962), tumour necrosis factor alpha (TNF-308, -238) and interleukin-6 (IL6-174, nt565) were genotyped in 303
Caucasian (Czech) patients with TJA (89 with PJI / 214 without PJI), and 168 unrelated healthy Czech individuals
without TJA. The results showed that carriers of the less common IL1B−511*T allele were overrepresented in the
group of TJA patients with PJI (69%) in comparison with those that did not develop PJI (51%, p = 0.006,
pcorr = 0.037) and with healthy controls (55%, p = 0.04, pcorr = N.S.). There was no significant difference in the
distribution of the remaining five investigated CGPs and their haplotypes between groups.
Conclusion: A functional variant of the gene encoding for IL-1beta was preliminarily nominated as a genetic factor
contributing to the susceptibility to PJI. Our results should be independently replicated; studies on the functional
relevance of IL1B gene variants in PJI are also needed.Background
Prosthetic joint infection (PJI) is a feared complication
of total joint arthroplasty (TJA) regardless of the site.
Current estimates suggest that despite careful manage-
ment to avoid all possible sources of infection, PJI can
exhibit in up to 1.7% of primary hip arthroplasties and
2.5% of primary knee arthroplasties [1,2]. Majority of PJI
is tightly linked to intraoperative contamination of
implanted device. It was repeatedly demonstrated that
any medical device implanted into the host body impairs
local innate host response facilitating development of PJI
[3]. Therefore rigorous preventative measures have been
introduced into the clinical practice to diminish intrao-
perative microbial exposure and increase the likelihood
that the host immune response together with antibiotics
will tackle remaining bacterial load [4]. In this line, each* Correspondence: jiri.gallo@volny.cz
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reproduction in any medium, provided the orpatient undergoing TJA should have the same chance
for PJI. However, majority of patients did not experience
PJI; hence there is a question why some patients cannot
escape the fate of PJI.
It has been suggested that patients with PJI could have
a defect in their immune response [5]. Recognition of
the bacteria by pattern-recognition receptors (PRRs)
leads to intracellular signal transduction by adaptor
molecules that across several cascades induce increased
expression of proinflammatory cytokines and their re-
lease from inflammasomes [6,7]. Of these the most
prominent roles are played by interleukin (IL)-1beta and
IL-18 that trigger the complex inflammatory response
together with the participation of other proinflammatory
mediators such as IL-6 and tumour necrosis factor
(TNF) alpha [8]. These cytokines regulate the recruit-
ment, activation, proliferation and differentiation of im-
mune cells in order to eliminate the local microbial
burden. Interindividual variability in cytokine production
has been observed, and these variations are suspected to
be genetically determined, most frequently via the effectsral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Basic characteristics of the patients with total
joint arthroplasty (TJA) with prosthetic joint infection
(PJI) and those without PJI (aseptic TJA)
PJI Aseptic TJA p Value
Patients; N 89 214
Gender; Men/Women 44/45 67/147 p = 0.003
Age at index surgery; years 63 (52–69) 47 (42–51) p < 0.001
Joint; hip/knee/other* 39/47/3 202/12/0 p< 10-5








Other pathogens 17 n.a.
Negative 18 n.a.
Primary diagnosis: p< 10-5
Osteoarthritis 68 58
Dysplastic joint 7 96
Inflammatory arthritis 3 10
Other diagnoses 11 50
Comorbidity:
DM 11 18 p = 0.29
RA 2 11 p = 0.42
other 21 49 p= 1.0
no 55 136 p = 0.77
Legend: Continuous data presented as median with interquartile (1st to 3rd)
range in parentheses.
p values for comparison between the groups of patients with/without PJI were
calculated by Chi-square test (Pearson’s) with appropriate degrees of freedom
(d.f.), Fisher exact test or Mann–Whitney U test according to the type of data.
*Shoulder, elbow.
BMI, body mass index; DM, diabetes mellitus; n.a., not applicable; RA,
rheumatoid arthritis.
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kine genes [9-11]. Accordingly, relevant functional poly-
morphisms in the cytokine genes may be implicated in
the pathogenesis of PJI for instance via impairing the ef-
fector (post-recognition) phase of the innate immune re-
sponse. In this study, we hypothesized that frequency of
particular variants of the genes encoding for a set of
proinflammatory cytokines differs significantly between
the patients exhibiting and avoiding PJI.
Methods
Study population
Between February 2004 and October 2010, blood sam-
ples were collected by venopuncture from 303 Czech
patients with TJA. A target group consisted of 89
patients with PJI. Of them majority were the patients
that were treated for PJI at the Department of Orthopae-
dics, University Hospital Olomouc between January
1998 and June 2010 (N= 73). To increase the number of
PJIs and thus the power of the study, the orthopaedic
departments in Frydek Mistek (N= 11) and Znojmo
(N= 5) both in the Czech Republic, were asked to recruit
patients treated for PJI at these departments. A control
group with TJA (N= 214) was created from patients who
did not experience PJI up to the date of blood sampling;
they were reoperated at the Department of Orthopae-
dics, University Hospital Olomouc for aseptic loosening
and periprosthetic osteolysis or still had a functional pri-
mary prosthesis (Table 1). Majority of patients with total
hip arthroplasty (> 80%) had a cementless implant while
all knees were cemented.
In addition, 168 healthy people without TJA were
recruited as a population control group [age, median
(1st-3rd quartile): 28(24–34); males/females: 91/77]. All
patients and controls were unrelated individuals of
Czech Caucasian origin (Figure 1). The informed con-
sent for the anonymous use of their DNA for the pur-
poses of this study was obtained from all subjects. The
study was performed with the approval of the local Eth-
ics Committee.
Phenotype definitions
Patients with PJI was diagnosed according to the previ-
ously published criteria [12]: 1) presence of sinus tract
communicating with a joint and/or intra-articular pus; 2)
coincidentally positive results of histological examination
(five or more neutrophils per high power field) and culture
of intraoperative samples; 3) if only intraoperative culture
or histological results were positive, then high clinical sus-
picion of infection (either experienced as acute onset,
fever, erythema, edema, and joint pain or persistent local
pain, early prosthetic failure, history of wound healing dis-
turbances, etc.) had to be present together with at least
two of the following tests: erythrocyte sedimentation rate>30 mm/hr, C-reactive protein elevated more than 1.5
times above the laboratory reference value, positive 99m
Technetium leukocyte scintigraphy (the latter criterion
related only to the patients from the University Hospital
Olomouc). The patients without PJI did not fulfil the
above mentioned criteria for PJI.
Candidate cytokine gene variants and genetic analysis
A crucial role of cytokines TNFalpha, IL-1beta and IL-6
in mediation and amplification of the immune response
to bacterial pathogens, as described in the introduction,
nominates the genes for these cytokines as highly plaus-
ible candidates for implication in the susceptibility to PJI.
Accordingly, we selected six functional single nucleotide














Figure 1 Flowchart of the study design. TJA – Total Joint
Arthroplasty; PJI – Prosthetic Joint Infection.
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rs16944; IL1B+ 3962, rs1143634) and IL-6 (IL6-174,
rs1800795; IL6 nt565, rs1800797). Chosen SNPs became
the most widely studied within particular cytokine genes
for their possible association with diseases (http://www.
ncbi.nlm.nih.gov/projects/SNP). The genotyping was per-
formed in all subjects by means of the polymerase chain
reaction with sequence-specific primers (PCR–SSP)
using the original Heidelberg kit (Cytokine CTS – PCR-
SSP Tray kit, product No. 124, University of Heidelberg,
Heidelberg, Germany) according to the manufacturer’s
instructions. Briefly, DNA was extracted from peripheral
blood by the standard salting-out procedure [13] and
obtained DNA was handled according to ethical rules.
The PCR mix consisting of original “master” mix, Taq
DNA polymerase (TopBio, Prague, Czech Republic) and
template DNA was added to the lyophilised primers on
the typing tray. The cycling conditions for PCR-SSP were
as follows: 94°C - 2 min (initial denaturation), 10 cycles
(94° - 15 sec, 65°C - 1 min) and further 20 cycles (94°C –
15 sec, 61°C – 50 sec, 72°C – 30 sec). PCR products were
visualized on the agarose gel electrophoresis using an
ethidium-bromide staining. The genotypes were deter-
mined based on the presence/absence of the allele spe-
cific and internal control bands. The nomenclature for
the investigated SNPs was adopted from the Heidelberg
kit manual. The typing kit was previously validated and
used by us [14,15] and many others [16]. In particular,
the genotype calling was tested in five of six investigated
SNPs (except of IL1B+ 3962) during the validation phase
by “in-house” PCR-based methodologies with almost ab-
solute concordance. The remaining SNPs from the
Heidelberg kit (not selected for this study) were omitted
from the analyses.Statistical analysis
Allelic and genotype frequencies and carriage rates were
calculated for all investigated polymorphisms by direct
counting [15]. The distribution of genotypes was tested
for conformity with the Hardy–Weinberg equilibrium
(HWE) using the chi-squared test [17]. The relationship
between the genotypes and clinical/demographic vari-
ables was tested by chi-square test (gender, primary
diagnosis/indication for TJA) or Mann–Whitney U test
(age at index arthroplasty, body mass index). Statistical
power of the study was calculated for each investigated
SNP based on the allele frequencies in the healthy con-
trol group according to protocol described elsewhere
[18].
Allelic, genotype and phenotype (carriage rates) fre-
quencies were compared between the patients with PJI
and both control groups using the standard chi-square
test. The frequencies of the haplotypes for the pairs of
IL1B, TNF and IL6 SNPs were estimated by expect-
ation–maximisation algorithm and the linkage disequi-
librium (LD) was tested using the likelihood ratio test
(software ARLEQUIN, version 3.000), [19]. In case of
subanalysis within the group of patients with PJI
(according to the type of PJI and the results of intrao-
perative culture) the Fischer exact test with two sided
p values was used to analyze the differences between
the groups. In all cases, a p value less that 0.05 was
considered significant and corrected for the number of
tested markers using the Bonferroni method.Results
To uncover any possible association between the func-
tional polymorphisms of the cytokine genes and PJI, six
selected SNPs (IL1B-511, IL1B+ 3962, TNF-308, TNF-
238, IL6–174, IL6 nt565) were genotyped in the TJA
patients with/without PJI and in the ethnically matched
healthy controls. The distribution of genotypes for all
investigated polymorphisms conformed to the HWE in
both control groups (with non-significant chi-squared
values); the distribution of IL1B-511 genotypes deviated
from the HWE in the PJI group (p = 0.02). No significant
relationship between genotypes of any of investigated
SNPs and clinical/demographic variables (gender, body
mass index, age at index arthroplasty, primary diagnosis/
indication for TJA) was observed. Statistical power of
the present study to detect a difference in minor allele
frequency between the groups of TJA patients with /
without PJI corresponding to odds ratio (OR) = 2
reached 98% for IL1B-511, 97% for IL1B + 3962, 94% for
TNF-308, 61% for TNF-238, and 99% for both IL6–174
and IL6 nt565 SNPs. The observed allelic and genotype
frequencies and carriage rates for the investigated poly-
morphisms are summarized in Table 2.
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morphism differed nominally between TJA patients with
PJI versus those without PJI (p = 0.014, pcorr > 0.05, 2
degrees of freedom), particularly due to the overrepre-
sentation of IL1B-511 CT heterozygotes and reciprocal
decrease of CC homozygotes among PJI patients. Im-
portantly, the proportion of carriers of the less common
IL1B-511*T allele was significantly higher in PJI
patients (69%) than in those that did not develop PJI
(51%, p = 0.006, pcorr = 0.037; odds ratio = 2.06, 95%CI:
1.22-3.47) or healthy controls (55%, p = 0.04, pcorr >
0.05; odds ratio = 1.76, 95%CI: 1.02-3.02), (Figure 2).
Similarly, the allelic frequency of IL1B-511*T tended
to be higher in the group of PJI patients by comparison to
those with “aseptic” TJA (p= 0.052). The alleles and geno-
types of the other five investigated cytokine gene poly-
morphisms were similarly distributed (p> 0.05) in all three
groups (Table 2).The frequencies of two-locus haplotypes
for each investigated cytokine gene estimated byTable 2 The genotype and allelic frequencies and carriage rat
(SNPs) of cytokine genes in 1) patients that developed prosth
PJI, N =89), 2) patients without prosthetic infection (TJA with
subjects (N= 168)









IL1B-511* CC 0.31 C 0.61 C 0.91 CC 0.49 C
CT 0.60 CT 0.42
TT 0.09 T 0.39 T 0.69 TT 0.10 T
IL1B
+ 3962
CC 0.59 C 0.76 C 0.94 CC 0.57 C
CT 0.35 CT 0.35
TT 0.06 T 0.24 T 0.41 TT 0.08 T
TNF-308 GG 0.74 G 0.85 G 0.96 GG 0.72 G
GA 0.21 GA 0.25
AA 0.04 A 0.15 A 0.26 AA 0.03 A
TNF-238 GG 0.91 G 0.96 G 1.00 GG 0.93 G
GA 0.09 GA 0.07
AA 0.00 A 0.04 A 0.09 AA 0.00 A
IL6–174 GG 0.33 G 0.56 G 0.79 GG 0.36 G
GC 0.46 GC 0.43
CC 0.21 C 0.44 C 0.67 CC 0.21 C
IL6 nt565 GG 0.34 G 0.57 G 0.80 GG 0.38 G
GA 0.46 GA 0.43
AA 0.20 A 0.43 A 0.66 AA 0.19 A
The data are presented as relative values.
* IL1B-511*T carriage rate (Pearson’s Chi-square test, 1 degree of freedom, d.f.):
TJA with PJI versus TJA without PJI: p = 0.006, pcorr = 0.037; odds ratio = 2.06, 95%CI:
TJA with PJI versus HC: p = 0.04, pcorr > 0.05; odds ratio = 1.76, 95%CI: 1.02-3.02.
* Distribution of IL1B-511 genotypes (Pearson’s Chi-square test, 2 d.f.):
TJA with PJI versus TJA without PJI: p = 0.014, pcorr > 0.05.
* Allelic frequency of IL1B-511*T (Pearson’s Chi-square test, 1 d.f.):
TJA with PJI versus TJA without PJI: p = 0.052.expectation–maximisation algorithm are listed in Table 3.
Consistent with the previous reports we detected strong
LD between the alleles at two IL6 SNP loci (IL6-174 /
nt565, p < 0.00001 for all groups). The results from a sin-
gle locus analysis in IL1B gene were reflected also in a
haplotype level: The IL1B −511/ +3962 TC haplotype
tended to be more frequent in PJI patients by comparison
to those without infection after TJA. Nevertheless, overall
haplotype distribution did not significantly differ between
the PJI patients and those that did not develop PJI for any
of investigated IL1B,TNF and IL6 genes.
In order to reveal whether investigated polymorphisms
of cytokine genes may be associated with PJI in particu-
lar anatomical localization we further compared their
distribution separately in patients with total hip arthro-
plasty; this subanalysis could not be performed for knee
prosthesis due to the very low number of control
patients (N = 12). In compliance with the results in over-
all TJA groups (see Table 2), the patients with PJI of hipes of six investigated single nucleotide polymorphisms
etic joint infection after total joint arthroplasty (TJA with
out PJI, N = 214) and 3) the group of healthy control











0.69 C 0.90 CC 0.45 C 0.68 C 0.91
CT 0.46
0.31 T 0.51 TT 0.09 T 0.32 T 0.55
0.75 C 0.92 CC 0.61 C 0.78 C 0.96
CT 0.35
0.25 T 0.43 TT 0.04 T 0.22 T 0.39
0.85 G 0.97 GG 0.68 G 0.83 G 0.98
GA 0.30
0.15 A 0.28 AA 0.02 A 0.17 A 0.32
0.96 G 1.00 GG 0.92 G 0.96 G 1.00
GA 0.08
0.04 A 0.07 AA 0.00 A 0.04 A 0.08
0.58 G 0.79 GG 0.33 G 0.58 G 0.84
GC 0.51
0.42 C 0.64 CC 0.16 C 0.42 C 0.67
0.59 G 0.81 GG 0.33 G 0.59 G 0.85
GA 0.52
0.41 A 0.62 AA 0.15 A 0.41 A 0.67
1.22-3.47.
Table 3 Estimated frequencies of IL1B, TNF and IL6
two-locus (SNP) haplotypes in patients with prosthetic
joint infection after total joint arthroplasty (TJA with PJI),
those without infection (TJA without PJI) and Czech
healthy controls. Data are given as proportions (relative
numbers) of each possible haplotype
TJA with PJI TJA without PJI Healthy Controls
IL1B haplotypes
−511 / +3962
CC 0.398 0.476 0.479
CT 0.214 0.217 0.195
TC 0.367 0.272 0.304
TT 0.022 0.035 0.022
Overall LD p value 0.003 0.001 0.002
TNF haplotypes
−308 / -238
AG 0.107 0.152 0.170
GA 0.045 0.040 0.042
GG 0.848 0.808 0.789
AA 0.000 0.000 0.000
Overall LD p value 0.607 0.289 0.017
IL6 haplotypes
−174 / nt565
CA 0.433 0.407 0.411
CG 0.011 0.016 0.006
GG 0.556 0.577 0.580
GA 0.000 0.000 0.003
Overall LD p value <0.00001 <0.00001 <0.00001
LD – linkage disequilibrium.
For all comparisons of overall haplotype distribution between the groups:
p> 0.05.
Figure 2 The proportion of the carriers of less common IL1B-
511*T allele in the study groups. TJA – Total Joint Arthroplasty;
PJI – Prosthetic Joint Infection. The p values and odds ratio for
comparisons between the groups are provided in the Table 2.
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proportion (0.62) than those without PJI (N= 202, 0.50).
Although this difference was almost the same as in com-
parison of overall TJA groups, it did not reach statistical
significance due to the lower size of the subgroups.
In further subanalysis reflecting manifestation of
infection after TJA, the PJI patients were subdivided
according to the type of infection (early, delayed, haema-
togenous) and the results of intraoperative culture
(Staphylococci, other pathogens, negative culture) as
described in Table 1. Interestingly, the homozygotes for
the less common IL1B-511*T allele (TT) were absent in
the subgroup of PJI patients with culture positive for
Staphylococci (0%) by comparison to those with other
pathogens or a negative culture (23%, pcorr = 0.003). Recip-
rocally, the carriage of IL1B-511*C allele was significantly
associated with the culture positive for Staphylococci
among the PJI patients.
Discussion
In the present study, we investigated the potential
relationship between PJI and variability of the genes en-
coding for the key proinflammatory cytokines, namely
IL-1beta, TNFalpha and IL-6. Of these, a particular
IL1B gene promoter polymorphism was primarily nomi-
nated as the risk factor for PJI development. The argu-
ments in favour of this interpretation are: i) adequate
statistical power of the study; ii) biological relevance
with IL-1β being a potent inducer of local inflammatory
response; iii) the magnitude of statistical significance of
the observed association [20]. In addition, we revealed
an association between carrying of a particular IL-1
gene polymorphism and occurrence of a particular
causative microorganism.
Few reports so far have described any association be-
tween the risk of PJI and genes related to the immune
response. Malik et al. reported single centre data aimed
at several targets. They investigated 71 septic cases and
revealed the possible role of mannose-binding lectin(MBL) polymorphism in the pathogenesis of PJI [21].
These authors also associated PJI and polymorphism of
the vitamin D receptor which might be in linkage dis-
equilibrium with SNPs influencing on functionality of
innate immunity [5]. On the other hand, they failed to
reveal any association between septic failure of total hip
arthroplasty and polymorphism in the genes encoding
for IL-6 (as in our present study) and OPG/RANK/
RANKL [5,22,23].
Cytokine IL-1beta exerts a wide range of inflamma-
tory activities that are important in the context of the
host defence against infection [8,24,25]. Although we
have no direct explanatory evidence for an association
of IL1B with the PJI found in our study, we can specu-
late that individuals carrying particular IL1B genotypes/
haplotypes differ substantially in their production of
IL-1beta protein in response to infectious/ inflammatory
stimuli [26,27]. In this regard, the effect of IL1B gene
promoter polymorphisms and haplotypes to stimulated
IL-1beta production in vitro has repeatedly been
reported [28,29]. Besides we observed the association of
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of IL1B genotypes deviated from HWE in PJI group. We
are aware that such finding may generally indicate pro-
blems in genotyping particularly in a “normal” popula-
tion. However, we used the genotyping technique which
was previously validated and successfully tested in paral-
lel with an alternative procedure in our laboratory; fur-
thermore, our both control groups (patients without PJI
and healthy individuals) genotyped by the same tech-
nique were quite in HWE in regard to IL1B genotype
distribution (p > 0.4 in both groups). From these reasons,
a systematic bias introduced by a false genotyping is not
probable and observed deviation from HWE may reflect
real differences in the effects of particular IL1B geno-
types on PJI susceptibility.
Concerning observed negative correlation between
IL1B-511 TT genotype and the intraoperative culture
positive for Staphylococci it is tempting to speculate on
that staphylococci need less or even none host suscepti-
bility to induce PJI compared to other pathogens. How-
ever, to confirm the above hypothesis, we would need to
examine larger subgroups of patients. In fact, particular
variants/ defects of immune response genes may confer
susceptibility to infection caused by preferential
spectrum of pathogens that is in extreme form evident
in primary immunodeficiencies [30]. By analogy, patho-
gen(s) causative for PJI should always be taken into ac-
count in the studies searching for a genetic background
of infectious complications after TJA. On the other
hand, El-Helou et al. found no clinical association be-
tween TLR2 R753Q SNP and Staphylococcus aureus PJIs
despite the in vitro demonstration that this SNP down-
regulates the TLR2-dependent immune and inflamma-
tory response to Staphylococcus aureus [31].
The present study has limitations. First, the poly-
morphic variants of the immune-response genes are not
the only independent variable modifying the anti-
infection resistance of the patient. Several other factors
have been nominated as influencing the risk for develop-
ment of PJI. The research on the role of age, gender and
other potential confoundings relevant to resistance/ vul-
nerability to PJI is still continuing [32-35]. For instance,
aging should result in several structural and functional
changes in the immune system ("immune senescence")
which are generally associated with an increased risk for
infection in elderly [36,37]. However, there is still lack of
consensus regarding the age above which the immune
system is more prone to PJI. In fact, several studies did
not report the age being significant variable predicting
development of PJI [2,38-40]. Regarding gender, some
studies found a male gender to be more prone to PJI in
comparison to female gender [32,41] while others did
not confirm it considering male gender to be at least
neutral variable regarding the risk for PJI [40,42]. Thesame has been reported for diabetes mellitus, rheuma-
toid arthritis and other potential confounders even that
the effect of co-morbidities on the risk of PJI is widely
accepted [34,40,43,44].
Additionally, due to its size this study may be under-
powered for detection of small/moderate genetic effects
on PJI susceptibility; this applies namely for the rare
TNF-238 variant. Generally, genetic association studies
present their own set of uncertainties and challenges
that are deeply addressed in STROBE, STREGA, and re-
cently GRISP statements [45,46], however we tried to
address those in our study design & methodology, and
also acknowledge that the observed association is of a pre-
liminary character and specific for the Czech, Caucasian
population.
Perspectives for the future
There is no doubt that knowledge on a particular genetic
trace increasing significantly the risk for PJI develop-
ment could influence the outcomes of total joint arthro-
plasty. To achieve it there is necessary to increase the
number of subjects/controls included in the study
(multi-centre international collaborative projects) and to
improve the data collected in such study (each host-,
implant-surgery- and pathogen-related) with aim to re-
duce the potential influence of confounding on an
observed association. Secondly, multiple potential targets
should be analyzed together because it is likely that sus-
ceptibility to PJI is the result of polymorphisms from
multiple genes rather than one single mutation. It can
require testing simultaneously the set of at least thou-
sand of genes that has been determined as involved in
innate immune response. Finally, the research in the
field of pathogenesis of PJI (infection) should be strongly
supported in order to make genetic targets/mechanisms
biologically plausible.
Conclusion
In this study, we found an association between carriage
of IL1B-511*T allele and increased risk for PJI develop-
ment. We found no association between PJI and poly-
morphisms in the genes coding for TNFalpha and IL-6.
Our data suggest that a functional allelic variant of the
gene encoding for the cytokine IL-1beta may predispose
patients after total joint arthroplasty to the development
of PJI. This conclusion should, however, be considered
preliminary until being independently replicated, prefer-
ably by multicentre efforts/multinational consortia.
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